Tesamorelin

Stabilized GHRH analog (Egrifta) — FDA-approved for visceral fat reduction in HIV lipodystrophy.

Tesamorelin is the most clinically proven member of the GHRH family — an actual approved drug (Egrifta) with real trial data, originally for shrinking the deep visceral fat that builds up in HIV patients on older medications. That visceral-fat effect is exactly what makes it interesting to everyone else: it's one of the few peptides shown to target the dangerous fat packed around your organs rather than just the soft fat under the skin. It also raises IGF-1 and has shown cognitive signals in mild-cognitive-impairment trials. Stronger and far better documented than Sermorelin, it's the GHRH of choice when fat loss is the real goal.